What OSPRI does

OSPRI is a privately held molecular research reagent company founded in 2025 and headquartered in McKinney, Texas, with manufacturing and R&D operations in Tyler, Texas. The company develops and sells 120+ multiplex qPCR (quantitative polymerase chain reaction) reagent kits designed exclusively for laboratory research use, explicitly not for use in diagnostic procedures. Its product portfolio spans 11 categories: Antimicrobial Resistance, Dermatology, Ear/Nose/Throat, Gastrointestinal, Infectious Disease, Respiratory (24 kits), Sexual Health (26 kits), Streptococcal, Urinary Tract (18 kits), Women's Health (24 kits), and Wound. The company's core technical differentiator is its proprietary Direct-to-PCR (D2P) extraction-free workflow technology, which reduces protocol complexity from 15 steps to 9 steps, alongside quad-plex multiplexing capability enabling up to 4 targets per reaction well and configurations supporting up to 56+ targets per panel across a target library spanning 100+ bacterial, 50+ viral, 30+ fungal, 35+ antimicrobial resistance markers, and 15+ parasite/protozoa targets.

The company sells through a direct-to-customer e-commerce model with global distribution, supplemented by contact-based sales for custom configurations. Pricing is not publicly disclosed, and customers are directed to engage the sales team for quotes on custom reagent panels. Its primary customer segment is laboratory researchers — Ph.D. scientists, molecular biologists, and R&D teams conducting infectious disease, antimicrobial resistance, and microbiome studies — served through a horizontal segmentation approach across academic and commercial research institutions. Marketing relies on technical content, peer-reviewed publications, and white papers emphasizing workflow simplification and target coverage breadth, with leadership co-founder Dr. Rob E. Carpenter producing peer-reviewed research in next-generation sequencing and precision metagenomics as part of the external scientific engagement strategy.

OSPRI operates as a vertically integrated founder-led company with five co-founders (Steve M. Sorey, Jeremy Adamic, Randy Phelps, Dr. Alaina Vincent, and Dr. Rob E. Carpenter) and additional operational leadership including a VP of Strategic Operations (Kerrigan Keele, MS/MBA) and a CIO (Sadia Almas). The company has secured $30 million in funding from Catalio Capital Management and simultaneously acquired three entities on August 19, 2025: Advanta Genetics' R&D Division, Community Direct DX, and Scienetix — a consolidation move that expands R&D capacity, manufacturing know-how, and likely clinical-to-research translation capabilities. No institutional investor participation beyond Catalio is evidenced, and specific revenue, headcount figures, and patent holdings are not disclosed in the source material.

Name

OSPRI

Legal name

OSPRI

Website

https://ospribio.com

Company type

Private

Founded year

2025

Operating status

Operating

Headcount range

11–50 employees

Short description

OSPRI is a private molecular research reagent company that develops and sells 120+ multiplex qPCR reagent kits featuring extraction-free Direct-to-PCR workflow technology for laboratory research use across infectious disease, antimicrobial resistance, and other pathogen research applications.

Ownership category

akta.pro rank

Product category

Molecular Research Reagents

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413), Analytical Laboratory Instrument Manufacturing (334516)

SIC

Laboratory Analytical Instruments (3826), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Molecular Diagnostics (PCR/qPCR, NGS-based assays) (HLAAALAA)

akta.pro secondary industries

Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays) (HLAAALAL), Molecular & Genetic Testing (PCR/NGS/qPCR) (HLAGADAF)

Keywords

• Molecular research reagents
• QPCR reagent kits
• Multiplex diagnostics
• Direct-to-PCR technology
• Laboratory research supplies

Headquarters

HQ city

Mckinney

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Technology or R&D, Supply Chain, Infrastructure, Marketing or Sales

Revenue model

1. qPCR Reagent Kit Sales: OSPRI generates revenue through the sale of multiplex qPCR reagent kits. The company offers 120+ reagent configurations across various research areas including respiratory, gastrointestinal, sexual health, women's health, urinary tract, and antimicrobial resistance. Custom configuration requests are also available for specific research needs.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels3 records

Core offering

OSPRI develops and manufactures multiplex qPCR reagent kits for laboratory research applications, offering 120+ configurations across 11 research categories (respiratory, gastrointestinal, sexual health, women's health, urinary tract, infectious disease, dermatology, ear/nose/throat, streptococcal, wound, and antimicrobial resistance). The kits feature proprietary extraction-free Direct-to-PCR (D2P) workflow technology and quad-plex multiplexing (up to 4 targets per well), with vertically integrated R&D and manufacturing.

Product overview

OSPRI is a molecular research reagent company offering a unified portfolio of 120+ multiplex qPCR reagent kits for laboratory research applications. The product portfolio includes 11 distinct reagent kit categories spanning Antimicrobial Resistance, Dermatology, Ear/Nose/Throat, Gastrointestinal, Infectious Disease, Respiratory (24 kits), Sexual Health (26 kits), Streptococcal, Urinary Tract (18 kits), Women's Health (24 kits), and Wound applications. All reagent kits feature extraction-free Direct-to-PCR (D2P) technology and quad-plex multiplexing capability (up to 4 targets per reaction well), with customizable panel configurations from 1-well to 14-well formats supporting up to 56 targets per reagent configuration. The portfolio targets bacteria, viruses, fungi, parasites, protozoa, and antimicrobial resistance markers across diverse research areas.

Differentiator

Problem solved

Functional benefit

Products and services

• Respiratory Reagent Kits
• Sexual Health Reagent Kits
• Women's Health Reagent Kits
• Urinary Tract Reagent Kits
• Gastrointestinal Reagent Kits
• Wound Reagent Kits
• Dermatology Reagent Kits
• Streptococcal Reagent Kits
• Ear, Nose & Throat Reagent Kits
• Infectious Disease Reagent Kits
• Antimicrobial Resistance Reagent Kits

Quantifiable outcome

• 9-step workflow vs 15-step traditional extraction workflow
• +2 more outcomes

Segments2 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Qiagen: Qiagen is a global leader in molecular sample and assay technologies, offering a broad qPCR reagent portfolio that directly overlaps with OSPRI's multiplex qPCR kit catalog across infectious disease, AMR, and microbiome research applications.
• Bio-Rad Laboratories: Bio-Rad manufactures qPCR reagents and instruments (e.g., CFX systems) and competes head-to-head with OSPRI in research-use multiplex qPCR consumables for infectious disease and AMR workflows.
• Promega Corporation: Promega supplies molecular biology reagents including qPCR master mixes and assay systems, making it a directly comparable reagent vendor targeting research and clinical labs with similar customer personas to OSPRI's laboratory researcher segment.
• Meridian Bioscience: Meridian develops molecular diagnostic reagents and qPCR assays for infectious disease testing, comparable to OSPRI's multiplex reagent kit portfolio spanning respiratory, GI, and sexual health research applications.
• bioMérieux (BioFire): BioFire is the market-leading multiplex syndromic panel franchise (FilmArray), and its research-use multiplex qPCR chemistry is the most analogous competitor to OSPRI's quad-plex reagent platform.
• DiaSorin (Luminex): Luminex (now under DiaSorin) commercializes multiplex molecular testing platforms and reagent chemistries for infectious disease research, providing a directly comparable multiplexing technology competitor to OSPRI.

Broad incumbents

• Thermo Fisher Scientific: Through its Applied Biosystems brand, Thermo Fisher offers the dominant installed base of qPCR instruments and a deep catalog of TaqMan assays that overlap with OSPRI's reagent kits, but as part of a much broader life sciences portfolio rather than a focused multiplex reagent niche.
• Cepheid (Danaher): Cepheid operates the GeneXpert molecular diagnostic platform with proprietary qPCR chemistry, serving as a broad incumbent whose research-use reagents and instrument systems compete with OSPRI's lab researcher value proposition.
• Hologic: Hologic's Panther and Panther Fusion systems include multiplex molecular assays for sexual health and infectious disease — directly overlapping with OSPRI's sexual health, women's health, and respiratory research reagent categories.
• QuidelOrtho: QuidelOrtho develops Savanna and other molecular diagnostic platforms with multiplex qPCR chemistries, representing a broad-incumbent peer whose assay menu (respiratory, sexual health) overlaps with OSPRI's reagent catalog.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A3 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about OSPRI